Tyra Biosciences Inc Cash Flow-to-Debt Ratio
Tyra Biosciences Inc cash flow-to-debt ratio. Tyra Biosciences Inc (TYRA) has a Cash Flow-to-Debt Ratio of -1.01x as of December 2025, meaning its operating cash flow of $-23.62 Million could theoretically repay -1% of its total liabilities ($23.43 Million) in one year. See Tyra Biosciences Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tyra Biosciences Inc (2019–2025)
Cash flow-to-debt ratio of Tyra Biosciences Inc from 2019 to 2025. Historical debt coverage capacity for Tyra Biosciences Inc across 7 annual periods. Also explore net asset growth rate of Tyra Biosciences Inc to track the company's year-over-year net asset growth rate.
Tyra Biosciences Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Tyra Biosciences Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Tyra Biosciences Inc. For the full cash flow conversion analysis, see Tyra Biosciences Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.06x | $-95.14 Million | $23.43 Million | ▼ -18.8% |
| 2024 | -3.42x | $-69.77 Million | $20.41 Million | ▼ -47.3% |
| 2023 | -2.32x | $-50.14 Million | $21.59 Million | ▲ +61.4% |
| 2022 | -6.02x | $-50.28 Million | $8.35 Million | ▼ -25.9% |
| 2021 | -4.78x | $-23.75 Million | $4.96 Million | ▼ -1726.9% |
| 2020 | -0.26x | $-7.76 Million | $29.65 Million | ▲ +47.3% |
| 2019 | -0.50x | $-2.62 Million | $5.27 Million | — |